A Study of Nivolumab in Selected Uterine Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/110/a-study-of-nivolumab-in-selected-uterine-cancer-patients

Clinicaltrials.gov identifier:
NCT03241745 (https://clinicaltrials.gov/show/NCT03241745)

Study Contact Information:

Principal Investigator:
Claire Friedman, MD
by phone: 646-888-4247 or by email

About the Study

The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with metastatic or recurrent uterine cancer.

Nivolumab is a type of immunotherapy known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells. NOTE: This study is no longer enrolling.

This Study is Open To:

NOTE: This study is no longer enrolling.

This Study is Not Open To:

NOTE: This study is no longer enrolling.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.